Head-to-head evidence
MB12 vs Nivolumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
MB12
Developed by Laboratorio Elea Phoenix S.A.
NCT05668650 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.
Nivolumab
Marketed by Bristol-Myers Squibb
NCT01673867 · Phase 3 · completed
This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.
Next expected readout: December 2026 · NCT03527108 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MB12's landscape · Nivolumab's landscape